Neurocrine Biosciences Inc. (NBIX)
NBIX · Health Care · 
United States
Neurocrine Biosciences Inc. (NBIX) is a US company in the Health Care sector. The stock has its largest weight in XDEB (MSCI World Minimum Volatility), at 0.27%. Anyone who holds an ETF containing Neurocrine Biosciences also has an indirect stake in the company.
Data and Charts: Neurocrine Biosciences
Key Data for Neurocrine Biosciences
Neurocrine Biosciences Stock Price Chart
The Neurocrine Biosciences chart shows daily closing prices and is set to the current year by default. The stock is up 3.0% year to date and up 5.8% over twelve months. The last recorded close on October 30, 2026, was $146.10, at 37% of the 52-week range.
Price series from our database since Aug 12, 2024, 558 daily values.
Neurocrine Biosciences Stock Performance
| Year to date | +3.0% | 1 year | +5.8% |
|---|---|---|---|
| 1 month | +3.0% | 3 months | -12.4% |
| Calendar year 2025 | +3.9% |
Measured in euros, Neurocrine Biosciences is up 8.3% year to date and up 9.4% over twelve months. The difference from the dollar figures above comes from the exchange rate alone. Each daily price is converted at the ECB euro reference rate for that day.
Alysly Data Analysis: Neurocrine Biosciences
What ETF Is Neurocrine Biosciences In?
Neurocrine Biosciences has above-average ETF coverage and is held by 17 of the 104 ETFs we track, which together follow 8 indices. That puts the stock in more ETFs than 77.7% of the 4,341 stocks we track.
| ETF | Index | Weight | per €1,000 in the ETF |
|---|---|---|---|
| XDEB | MSCI World Minimum Volatility | 0.27% | €2.75 |
| XUHL / XUHC | MSCI USA Health Care | 0.21% | €2.08 |
| XDWH | MSCI World Health Care | 0.15% | €1.54 |
| SPFS | MSCI World Health Care | 0.15% | €1.52 |
| SPYI / SPSA | MSCI ACWI IMI | 0.05% | €0.47 |
| XD9U / XD9D | MSCI USA | 0.02% | €0.21 |
| EUNL | MSCI World | 0.02% | €0.20 |
| SWWD | MSCI World | 0.02% | €0.18 |
| SPPW | MSCI World | 0.02% | €0.18 |
| WIMI | MSCI World IMI | 0.02% | €0.16 |
| XDWD / XDWL | MSCI World | 0.02% | €0.16 |
| SPYY | MSCI ACWI | 0.01% | €0.12 |
| IUSQ | MSCI ACWI | 0.01% | €0.10 |
The last column shows how much of €1,000 in one of these funds goes to Neurocrine Biosciences, based on each fund's latest holdings list.
US-listed ETFs holding Neurocrine Biosciences (weight per latest SEC filing): ONEQ 0.03%, VTI 0.02%. These funds are registered in the US; retail investors in the EU usually cannot buy them.
Neurocrine Biosciences Weight in iShares Core MSCI World (EUNL) Since 2019
In iShares Core MSCI World (EUNL), Neurocrine Biosciences had a weight of 0.02% on Dec 31, 2019 and 0.02% on Oct 29, 2026. The fund tracks the MSCI World. Its share peaked at 0.03% on Jun 30, 2020. The weight rises and falls with the stock's price performance relative to the other index members. It can also change when the index provider adjusts the index composition.
What's Inside Your ETF Portfolio and the ETF overlap check show how much Neurocrine Biosciences overlaps with the rest of a portfolio.
Which Tracked Investors Hold Neurocrine Biosciences?
Neurocrine Biosciences is not among the largest purchases in the quarter ending Jun 30, 2026. The list is led by GOOGL, DAL and NEBIUS GROUP N.V. The only manager we track that holds Neurocrine Biosciences increased its position.
| Investor | Shares | Value | Quarter |
|---|---|---|---|
| Bridgewater Associates | 205,677 | $35M | increased by 57,536 |
As of Jun 30, 2026. Based on quarterly filings with the US securities regulator, submitted up to 45 days after the reference date. The change counts shares, not price gains.
Stocks With ETF Exposure Similar to Neurocrine Biosciences
| Stock | Shared ETFs | r | 1 year | Annualized volatility | Net margin | Revenue growth |
|---|---|---|---|---|---|---|
| Neurocrine Biosciences | – | – | +5.8% | 36.2% | 16.7% | +21.4% |
 Insmed Incorporated | 16 | – | -42.0% | 54.9% | -210.5% | +66.7% |
 Medline | 16 | – | – | 43.8% | 4.1% | +11.5% |
 Natera | 16 | – | +114.4% | 46.7% | -9.0% | +35.9% |
 Roivant Sciences | 16 | – | +88.5% | 39.4% | -3,629.2% | -71.6% |
 Revolution Medicines | 16 | – | +225.0% | 56.2% | – | – |
 United Therapeutics Corporation | 17 | – | +32.0% | 41.2% | 41.9% | +10.6% |
 McKesson Corporation | 17 | – | +20.5% | 28.4% | 1.2% | +12.4% |
| Alnylam Pharmaceuticals Inc | 17 | – | -63.3% | 48.0% | 8.4% | +65.2% |
These stocks reach a portfolio through largely the same funds as Neurocrine Biosciences. “Shared ETFs” counts the funds that hold both.
Return and volatility are calculated from our daily closing prices in US dollars. Margin and growth come from each company's latest SEC annual filing. Because fiscal years do not end on the same date for every company, the underlying periods are not fully identical.
Fundamental Analysis: Neurocrine Biosciences
Neurocrine Biosciences Key Financials
Figures come from the SEC annual filing for the latest reported fiscal year (period end Dec 31, 2025).
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| FY ended Dec 2023 | 1.9 | 0.2 | 13.2% |
| FY ended Dec 2024 | 2.4 | 0.3 | 14.5% |
| FY ended Dec 2025 | 2.9 | 0.5 | 16.7% |
Technical Analysis: Neurocrine Biosciences
Neurocrine Biosciences Risk Metrics
The close on Oct 30, 2026, was 21.2% below the highest close since Aug 12, 2024. That high was reached on Jul 30, 2026. When the S&P 500 rose or fell 1%, Neurocrine Biosciences moved 0.59% on average in the same direction (past 252 trading days). The correlation of 0.23, however, shows only a moderate link to the broad market. Accordingly, moves in the S&P 500 explain only a small part of the daily price moves of Neurocrine Biosciences.
What Neurocrine Biosciences Correlates With
| Instrument | r | −1 … +1 |
|---|---|---|
| Incyte Corporation | +0.47 | |
| T. Rowe Price Group Inc. | +0.46 | |
| Apple Inc. | +0.42 | |
| Vertex Pharmaceuticals Incorporated | +0.40 | |
| Roblox Corp. Class A | +0.37 | |
| Royalty Pharma Plc Class A | +0.37 | |
| SAPIEN | -0.36 | |
| GIGGLE | -0.35 | |
| Nikkei 225 | -0.31 |
The strongest co-movers are listed at the top, the strongest inverse movers at the bottom. Low or negative correlations can help spread risk more broadly across a portfolio.
